In recent developments, Johnson & Johnson’s innovative IL-23-blocking oral peptide, icotrokinra, has demonstrated significant potential in treating autoimmune conditions, particularly psoriasis and inflammatory bowel disease (IBD). As a convenient oral alternative to injectable treatments, icotrokinra offers enhanced patient compliance and ease of administration. Recent clinical trials have shown that this novel treatment effectively reduces inflammation by targeting the IL-23 pathway, a critical factor in the inflammatory process. The results highlight substantial improvements in patient symptoms and a favorable safety profile, positioning icotrokinra as a strong candidate in the field of oral immunotherapies. The growing body of evidence supporting icotrokinra’s efficacy and safety could mark a pivotal shift in how chronic inflammatory diseases are managed. With further studies underway, Johnson & Johnson continues to strengthen its portfolio in the biopharmaceutical sector.
The Pharma LetterNew data shows when missile sirens are most likely in Israel
March 6, 2026
In Israel, missile sirens are an all-too-common occurrence, prompting citizens to seek safety often at the most inconvenient times. Newly analyzed data reveals a surprising